Additionally, the data identified potential roles of BCL6 and TP53 pathways in ME/CFS etiology and emphasized the importance of investigating adverse reactions to medication and supplements and drug interactions in ME/CFS severity and progression. This evidence concerns the gene TP53 and myalgic encephalomeyelitis/chronic fatigue syndrome.